OKUR OKUR
Company Profile ↓Company Overview
OKUR (OKUR) is a publicly traded company listed on with a market capitalization of $56.88M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +92.15% |
| 6 Months: | +73.33% |
| 3 Months: | -7.96% |
| 1 Month: | -5.02% |
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)50.39 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.00M | 16.32M | 15.50M | 14.12M | 15.62M |
| Operating Income | -4.50M | -3.70M | -5.10M | -7.21M | -9.23M | -12.75M | -13.02M | -12.43M | -13.84M | -16.12M | -21.04M | -20.89M | -9.83M | -14.34M | -11.51M | - | -17.00M | -16.32M | -15.50M | -14.12M | -15.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.79M | -15.18M | -14.49M | -13.29M | -15.41M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 2.00K | 6.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.93M | -15.39M | -14.70M | -13.50M | -15.16M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.43M | -3.69M | -5.09M | -7.21M | -9.22M | -12.73M | -13.04M | -12.31M | -13.01M | -15.11M | -19.53M | -19.20M | -9.54M | -14.14M | -11.56M | -17.44M | -15.93M | -15.39M | -14.70M | -13.50M | -15.16M |
| Diluted EPS | - | - | - | -3.48 | -0.43 | -0.52 | -0.53 | -0.50 | -0.53 | -0.60 | -0.65 | -5.68 | -30.37 | -44.82 | -36.55 | - | -1.19 | -1.14 | -1.09 | -0.99 | -1.11 |
| R&D Expense | 3.58M | 2.82M | 4.43M | 5.47M | 6.28M | 9.32M | 9.28M | 8.13M | 9.94M | 10.99M | 14.40M | 13.62M | 8.57M | 10.75M | 10.12M | - | 13.01M | 12.61M | 11.91M | - | 11.71M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 29.77M | 36.93M | 54.39M | 62.95M |
| Operating Income | -19.55M | -39.82M | -29.77M | -36.93M | -54.39M | -62.95M |
| EBITDA | - | - | -29.38M | -34.75M | -51.71M | -58.68M |
| Interest Expense | - | - | - | 0 | 300.00K | 8.00K |
| Pretax Income | - | - | -29.51M | -35.31M | -52.67M | -59.52M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -19.46M | -39.77M | -29.51M | -35.31M | -52.67M | -59.52M |
| Diluted EPS | -9.60 | -2.19 | -2.21 | -2.65 | -15.28 | -4.40 |
| R&D Expense | 15.94M | 28.17M | 37.70M | 32.12M | 43.80M | 48.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 55.22M | 154.02M | 16.00M | 35.73M | 114.91M | 62.12M |
| Current Assets | - | - | - | 13.62M | 33.77M | 113.00M | 60.84M |
| Cash & Equivalents | - | 53.61M | 124.66M | 11.54M | 29.88M | 110.76M | 59.05M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.62M | 6.81M | 70.42M | 137.58M | 11.08M | 5.93M |
| Current Liabilities | - | 4.58M | 6.20M | 5.54M | 7.29M | 10.53M | 5.92M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 637.00K | 674.00K | 1.08M | 549.00K |
| Total Equity | -23.13M | -42.12M | 147.21M | -54.42M | -101.84M | 103.83M | 56.18M |
| Shares Outstanding | - | - | - | 13.34M | 13.34M | 13.35M | 13.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.54M | -37.98M | -26.95M | -34.55M | -51.12M | -51.83M |
| Investing Cash Flow | 7.38M | -23.38M | -1.13M | -246.00K | 15.87M | -46.00K |
| Financing Cash Flow | 47.27M | 132.41M | 26.46M | 53.12M | 116.13M | 163.00K |
| Capital Expenditure | -24.00K | -198.00K | -1.13M | -246.00K | -52.00K | -46.00K |
| Free Cash Flow | -18.56M | -38.18M | -28.09M | -34.79M | -51.17M | -51.87M |
| Net Change in Cash | - | - | -1.62M | 18.33M | 80.89M | -51.71M |
| Share Buybacks | - | - | - | 4.40M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 46.2% | -27.0% | 54.2% | 34.7% | -50.7% | -105.9% |
| ROCE % | -38.6% | -26.9% | -284.7% | -129.8% | -52.1% | -112.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OKUR
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5IRGJRUktScHRpSTV1TmtWRkI5VVBVOU1mZEYteGkxOWtCc3hPWW5tMVBRWlVlNldLNUtCbVlEblFPaW1HOUxqbEduSlhGTHVOTjdkLVdMWkFDZ2FuMVpuUkEwaENtSXlOc25CZ2wxQ20xNV9jc2o4?oc=5" target="_blank">OnKure …
Breast cancer, vascular drug push gets OnKure $150M and a 2029 runway - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPaDlFYXVfU0VPZTNzN2RrWEM0amZNLVFUaGxtcWJBU3ZiMHd1amNPRDNGM0tQd2ZRd2lOa3dNVlVHdkZjODIxNTZLbnJxZHdWdUd4dHRvMDZEeWZtZGxzX2c3TTVmTWV1R0ZDSngzRk9uMUxieEVfdzRoeVRfSlUwbGVQdG82M3VWcFlzMU…
We're Not Very Worried About OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVHVvOXdsakJYVGlsU1hXM1lOTnFqeV9udFktc2FCSDZQSXF0LVJLUERIbU5zODlURkJzTV9KWm40X1dyQjQwLUlUQzNNSXVjRkVYeXlfM1ZRQnZ6bjh5a1RfVVowSDVMbHYwSHFFWjFBd2wyNlAwamZOUzQ0eG9GRkdRekQ2QUttcU9oc0…
OKUR Shares Face Turbulence Amid Financial Downturn - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTFBRbUtSZlg4dmxKLVFHSGJsUWRjT2t3LWMxSF9mU3dBR0hHeHFTdmw1Wm84LV8wRHV6NTgzQ2tGWEVZb1JTb2JoeURfNXN2Sl9ULU9VejBUWHduWjE4S3NQLUptVDR6cXlwclJBQXpjSlRfeTgyTjNyTVFUZW52Y1U?oc=5" target="_bla…
OKUR|Onkure Therapeutics Inc|Price:3.820|Chg%:-0.180 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5Zb2RFNlIyeXVlMS1SSWlPSUVUa1FEVVNnVHZUMkZtREFhUFBYbUNoeVhaRnhlaUxDekw4Yjc1QnJXTG5kYWQ5NkgtOG9JQWhXWG1GX0k0NTJyM0tUazhrWllNenJDNHNHUWkwY01n?oc=5" target="_blank">OKUR|Onkure Therape…
OnKure Therapeutics (OKUR) Falls 4.5% to $3.82: Support at $3.63 Faces Key Test - ETF Outflow Streak - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNaG1iV2ZBcGlMM3N4dFpBc0ZVaFZYbGVUVE81MDNMYWN3ZUs1ekxwLV9ZeG1VYjdJdjRCRmhaOWYwVTVqNVd1eWFjSXBIRjNDN0o1WHNPenhmeDN2ckM0T0g0VE16MnVROTI0dDI1Q01QNVdSS0RtZV9IOElMOURXYVFtY0lkX0k5QTd6bn…
OKUR — Frequently Asked Questions
What is the current share price of OKUR?
As of 2026-08-05 17:25 PDT, OKUR trades at $4.16 on NASDAQ/NYSE. Its 52-week range is $2.00 to $5.27.
What is the market capitalisation of OKUR?
OKUR has a market capitalisation of $56.88M on NASDAQ/NYSE.
What is the P/E ratio of OKUR?
OKUR trades at a trailing price-to-earnings (P/E) ratio of -0.95. Its price-to-book (P/B) ratio is 1.01.
What is the return on equity (ROE) of OKUR?
OKUR has a return on equity (ROE) of -105.93%. Its return on capital employed (ROCE) is -112.02%.
Is OKUR a good stock to buy?
This page provides a data-driven analysis of OKUR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.